Jynarque 60MG/30MG
Ended Awarded
- Contract number
- 36C24523N0403
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $12,196
Award facts
- Contract value 100% obligated
- $12,195.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
Award details come from SAM.gov/FPDS.
About this award
Otsuka America Pharmaceutical Inc., a specialty pharmaceutical manufacturer headquartered in Rockville, Maryland, received a delivery order award from the Department of Veterans Affairs (VA) Veterans Integrated Service Network 5 on March 8, 2023, for the supply of Jynarque (tolvaptan) 60mg/30mg. This firm-fixed-price contract, valued at $12,195.72, carries an ultimate completion date of March 10, 2023, and is issued for delivery to Pittsburgh, Pennsylvania. The award is issued under the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and does not utilize any set-aside designation, reflecting Otsuka's established status as a large federal pharmaceutical contractor.
This delivery order is executed under Otsuka America Pharmaceutical Inc.'s larger Blanket Purchase Agreement with the VA's National Acquisition Center, a comprehensive $83.3 million indefinite delivery vehicle that enables procurement of Jynarque across multiple VA Integrated Service Networks nationwide through March 26, 2026. Jynarque is utilized to treat autosomal dominant polycystic kidney disease and hyponatremia in veteran populations. The delivery order structure allows VA facilities to efficiently procure specialized pharmaceutical treatments while maintaining cost predictability through the firm-fixed-price mechanism, supporting the VA's mission to provide critical therapeutic medications to veterans across the United States.
Quick answers
Who was awarded contract 36C24523N0403?
36C24523N0403 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 5 (Veterans Health Administration) on March 8, 2023.
How much is contract 36C24523N0403 worth?
The government has obligated $12,196 on 36C24523N0403.
Is contract 36C24523N0403 an order under another contract?
Yes. 36C24523N0403 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24523N0403 competed?
The extent of competition for 36C24523N0403 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award